Published in J Neurooncol on July 01, 2003
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst (2009) 3.52
Predicting behavioral problems in craniopharyngioma survivors after conformal radiation therapy. Pediatr Blood Cancer (2009) 0.98
Developing a health-related quality of life instrument for childhood brain tumor survivors. Childs Nerv Syst (2006) 0.96
The clinical utility of health-related quality of life screening in a pediatric inflammatory bowel disease clinic. Inflamm Bowel Dis (2013) 0.91
Executive functions and social skills in survivors of pediatric brain tumor. Child Neuropsychol (2012) 0.85
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. Childs Nerv Syst (2014) 0.85
Behavioral, Social, and Emotional Symptom Comorbidities and Profiles in Adolescent Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol (2016) 0.78
Improving Care in Pediatric Neuro-oncology Patients: An Overview of the Unique Needs of Children With Brain Tumors. J Child Neurol (2015) 0.78
Long-term psychiatric outcomes in pediatric brain tumor survivors. Childs Nerv Syst (2015) 0.76
Adolescent and Young Adult Survivors of Childhood Brain Tumors: Life After Treatment in Their Own Words. Cancer Nurs (2016) 0.75
Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. Cancer (2016) 0.75
Baby Steps to Superintelligence: Neuroprosthetics and Children. J Evol Technol (2012) 0.75
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2012) 2.04
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol (2008) 1.92
Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer (2011) 1.91
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80
Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer (2010) 1.76
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics (2007) 1.67
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology (2013) 1.62
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol (2008) 1.33
PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther (2005) 1.28
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol (2008) 1.22
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res (2005) 1.16
Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension (2011) 1.16
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer (2011) 1.15
Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol (2014) 1.15
Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol (2008) 1.14
Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol (2005) 1.13
Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol (2014) 1.12
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn (2011) 1.11
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer (2010) 1.09
Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res (2011) 1.09
Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A (2013) 1.08
Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp Biol Med (Maywood) (2008) 1.04
Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med (2004) 1.03
Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer (2010) 1.03
DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One (2012) 1.02
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer (2013) 1.01
Brainstem lesions in neurofibromatosis type 1. Neurosurgery (2007) 1.01
Everyday cognitive function after craniopharyngioma in childhood. Pediatr Neurol (2006) 1.01
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer (2011) 1.00
Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol (2008) 1.00
Development of a parent-report cognitive function item bank using item response theory and exploration of its clinical utility in computerized adaptive testing. J Pediatr Psychol (2011) 1.00
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2013) 0.97
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res (2006) 0.95
Future of clinical genomics in pediatric oncology. J Clin Oncol (2013) 0.95
Angiogenesis inhibitors and hypoxia. Nat Med (2003) 0.94
Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs (2003) 0.94
Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. Pediatr Blood Cancer (2009) 0.94
Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer (2013) 0.93
Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet A (2008) 0.93
Parent-perceived child cognitive function: results from a sample drawn from the US general population. Childs Nerv Syst (2010) 0.92
DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium. Childs Nerv Syst (2010) 0.92
Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol (2011) 0.92
Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol (2006) 0.92
Pulmonary vein stenosis: expression of receptor tyrosine kinases by lesional cells. Cardiovasc Pathol (2006) 0.92
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer (2014) 0.90
Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol (2012) 0.90
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer (2014) 0.89
Remission of infantile generalized myofibromatosis after interferon alpha therapy. J Pediatr Hematol Oncol (2008) 0.88
Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med (2010) 0.88
Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics (2011) 0.87
A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children. Congenit Heart Dis (2011) 0.86
Small molecule inhibitors in children with malignant gliomas. Pediatr Blood Cancer (2009) 0.86
Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. Am J Pathol (2013) 0.85
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro Oncol (2011) 0.85
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol (2011) 0.85
Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery (2003) 0.85
Chemotherapy for progressive low-grade gliomas in children older than ten years: the Dana-Farber experience. Pediatr Hematol Oncol (2003) 0.84
New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res (2013) 0.84
Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer (2010) 0.83
Cutaneovisceral angiomatosis with thrombocytopenia. Pediatr Dev Pathol (2005) 0.82
Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol (2003) 0.82
The growing role of eicosanoids in tissue regeneration, repair, and wound healing. Prostaglandins Other Lipid Mediat (2013) 0.82
PPARs: A Double-Edged Sword in Cancer Therapy? PPAR Res (2009) 0.82
Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. J Neurosurg Pediatr (2014) 0.81
Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol (2013) 0.81
Pediatric neuro-oncology: current status and future directions. Asia Pac J Clin Oncol (2012) 0.81
Family factors associated with academic achievement deficits in pediatric brain tumor survivors. Psychooncology (2012) 0.80
Suicide ideation in pediatric and adult survivors of childhood brain tumors. J Neurooncol (2013) 0.80
Quantification of water diffusion and relaxation times of human U87 tumors in a mouse model. NMR Biomed (2004) 0.79
Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome. Pediatr Dermatol (2014) 0.79
Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. Future Oncol (2012) 0.79
A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatr Radiol (2012) 0.79
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs (2009) 0.78
Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol (2008) 0.78
Multidisciplinary pediatric brain tumor clinics: the key to successful treatment? CNS Oncol (2015) 0.78
Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent. J Pediatr Hematol Oncol (2009) 0.78
Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1. J Child Neurol (2010) 0.77
Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol (2016) 0.77
Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors. Curr Oncol Rep (2015) 0.77
Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer (2013) 0.76
Bone density in post-pubertal adolescent survivors of childhood brain tumors. Pediatr Blood Cancer (2011) 0.76
Psychological adjustment of 'surgery-only' pediatric neuro-oncology patients: a retrospective analysis. Psychooncology (2002) 0.76
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer (2012) 0.76
Epigenetics in clinical management of children and adolescents with brain tumors. Curr Cancer Drug Targets (2017) 0.75
Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases. J Pediatr Hematol Oncol (2017) 0.75